• Collin Jacobs, Peter Duewell, Klaus Heckelsmiller, Jiwu Wei, Franz Bauernfeind, Jonathan Ellermeier, Ulrich Kisser, Christian A Bauer, Marc Dauer, Andreas Eigler, Eugene Maraskovsky, Stefan Endres, and Max Schnurr.
• Department of Internal Medicine, University Hospitals, University of Munich, Munich, Germany.
• Int. J. Cancer. 2011 Feb 15; 128 (4): 897-907.

AbstractVaccines based on immune stimulatory complexes (ISCOM) induce T-cell responses against tumor antigen (Ag). However, immune responses are impaired in pancreatic cancer patients. We investigated the efficacy of an ISCOM vaccine in a murine pancreatic carcinoma model. Panc02 cells expressing OVA as a model Ag were induced subcutaneously or orthotopically in the pancreas of C57BL/6 mice. Treatment consisted of an OVA containing ISCOM vaccine, either used alone or in combination with the TLR9 agonist CpG. The ISCOM vaccine effectively induced Ag-specific CTL capable of killing tumor cells. However, in mice with established tumors CTL induction by the vaccine was inefficient and did not affect tumor growth. Lack of efficacy correlated with increased numbers of Treg. Depletion of Treg with anti-CD25 mAb restored CTL induction and prolonged survival. Adding low-dose CpG to the ISCOM vaccine reduced Treg numbers, enhanced CTL responses and induced regression of pancreatic tumors in a CD8(+) T cell-dependent manner. Mice cured from the primary tumor mounted a memory T-cell response against wild-type Panc02 tumors, indicative of epitope spreading. Combining ISCOM vaccines with TLR agonists is a promising strategy for breaking tumor immune evasion and deserves further evaluation for the treatment of pancreatic carcinoma.Copyright © 2010 UICC.

47 keywords...

hide…